-$0.16 EPS Expected for CEL-SCI Co. (NYSE:CVM) This Quarter

Analysts forecast that CEL-SCI Co. (NYSE:CVMGet Rating) will announce ($0.16) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for CEL-SCI’s earnings. CEL-SCI reported earnings of ($0.20) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 20%. The firm is scheduled to announce its next earnings results on Monday, January 1st.

On average, analysts expect that CEL-SCI will report full year earnings of ($0.49) per share for the current year. For the next fiscal year, analysts anticipate that the company will report earnings of $0.91 per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover CEL-SCI.

CEL-SCI (NYSE:CVMGet Rating) last announced its quarterly earnings results on Monday, February 14th. The company reported ($0.20) earnings per share for the quarter.

Separately, StockNews.com started coverage on shares of CEL-SCI in a report on Thursday, March 31st. They set a “sell” rating on the stock.

NYSE:CVM opened at $2.86 on Tuesday. The company has a debt-to-equity ratio of 0.25, a current ratio of 12.56 and a quick ratio of 11.94. The firm has a market cap of $123.77 million, a price-to-earnings ratio of -3.11 and a beta of 2.17. The company’s fifty day simple moving average is $3.86. CEL-SCI has a twelve month low of $2.62 and a twelve month high of $27.28.

About CEL-SCI (Get Rating)

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.

Read More

Get a free copy of the Zacks research report on CEL-SCI (CVM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.